Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It seems like another distributor. Similar to the American Regent deal, It is pending EUA/approval. So there is again no money involved, no EUA/approval in the Philippines. Was this really the news Nader was talking on the shareholder meeting? I certainly hope this isn't the "Big News" that he mentioned on the Fox interview.
CHIRAL PHARMA CORPORATION as Drug Importer|Wholesaler
Company Name: CHIRAL PHARMA CORPORATION
Address: P. Antonio St., cor. F. Legaspi St., Ugong, Pasig, Metro Manila
Activity: Drug Importer|Wholesaler
Owner: CHIRAL PHARMA CORPORATION
License Number: LTO-3000001899756
Validity of License: 11 November 2021
That was published in August, I thought they said it was more, I may be wrong, but nonetheless that was a hold up. NASDAQ was something I really wanted as it gave a level of credibility to the company, added some safeguards. I hope they are able to work something out. Maybe they are working out that Philippines deal to get us positive equity, and that is the hold up. I hope to hear something from that front as well. Nader stated possibly this week. Based on his history, I'm not counting on it, I think next CC there will be shareholders asking about it, and he will pivot to another topic, like Mexico, China, and the UK.
On one of the calls they stated that positive equity was needed as it was a requirement, I think we were -$4m or so and needed +$2m. I believe the company since stated they didn't want to raise capital at these levels, and since then we have closed below $3 a few times... So I don't know if that again changes the requirements needed. I'm not to confident that we are getting an uplist, it's been 11+ weeks now supposed to take 4-6 weeks. I'd rather the company focus on the BLA then uplist now anyway. If we don't get the CD-12 trail halted it's going to be a while before we get anything significant.
Traded over 2m yesterday what kind of vol are you looking for???
Tomorrow should be an eye opener. Shareholder meeting!
Anyone know what this notice of effectiveness is?
https://www.cytodyn.com/investors/sec-filings/all-sec-filings/content/9999999995-20-002582/9999999995-20-002582.pdf
Not necessarily, it could mean they are still gathering data, and going back and forth with the FDA. NOW, if by 10-10 we don't hear that it has been submitted, then yes we have an issue. We have that 30 day window where the FDA will look at everything provided and decide if we provided everything asked.
Big thing this week is will we hear a yes/no about NASDAQ. We have that shareholder meeting on Wed. If there is no news and Nader says Nasdaq is asking for more information...Then we have an issue. Personally I don't think we're going to get it. I think there is something they're not telling us, and if all we had to do is raise a small amount of capital to get positive equity then we would have.
To date we do not know if it has been submitted. The FDA gave them a 30 day window from the meeting 9-8 to get a rapid response if they met the requirements and could submit or if they still needed information. So 30 days from the meeting is 10-9.
Per the Dr. Been interview. So Nader did not say NO, Cytodyn/myself did not interfere in anyway with the paper, instead he gives a roundabout answer.
Dr. Mobeen Syed: Got it. So the last question, this may actually be a little hard, but I think that this has been asked so many times that it is interesting to us. And that is: Did someone block Doctor Patterson's paper from public publication?
Nader Pourhassan, CEO: So what is blocked? What do they mean? Blocked? Oh! Doctor Bruce Patterson has to be reached out to. To be fair to him. You can ask him that question. We enjoyed working with Dr. Patterson. Dr. Patterson had benefits for us. He is the one that gave us, told us, about the mechanism of action and what we have there already, is very strong. He was beneficial, we were beneficial to him, hopefully. We had a very [nintelligible]. W gave his laboratory a very large [order] based on how much he was getting. So, we had a good relationship, and that's all. His paper needs to be asked — our papers, we have like four or five papers that are now submitted... And we're gonna announce very soon [whether they get accepted or not.] And we have the CD
Per a conversation with Dr. Yo. posted on the FB group, they did twice on the Lancet and Nature, Bruce is going to re-write excluding Naders name.
That would be a better one to start than the nash, if we were to start another trial.
The company just doesn't have the bandwidth or resources to start and maintain multiple trials, it will cause these trials to be delayed. We can't even get 390 patients in CD-12
IMO we shouldn't be starting anymore trials for other indications until we have approval on at least 1. We have cancer and covid that we need to focus on, as have HIV that has yet to be approved. We need to be careful on how we allocate our funds. Although the 25m shares that management wants for compensation is worth $75m...
Are you hearing anything on the uplisting? I'm assuming we didn't get it.
Not lying, who's to say who is big? What kind of talks, was cytodyn trying to show them data, that's a talk. Only speculation what "in talks" means. We all would like it to be about a partnership or buy out... Did BP contact us, or did we reach out to BP. After this last CC with Naders talk about EUA I reread the PR and states requested, not applied, so that go me thinking, how did he request a mention on an email, a phone call? Was it formal, informal? Tricky words
That's why I'm saying they have to focus on enrolling CD-12 patients, not start new trials. This is a critical time for covid.
It will take a top notch management team to get it to the place of saving lives. Big money doesn't want cures and sure shots, then want medicine that works, but you need to keep on using it, so they make money. I very much believe BP forces are against us, but they don't have to work that hard with Nader captaining the ship. This is his baby, he is now too close, and too emotional. He's taken it to the 1 yard line, and now we need a stronger player to get it across the line. He's outlived his usefulness.
They NEED to focus on completing enrollment for CD12. We're just over 50% there 210 out of 390, chances are the DMSC will not halt the trial but will allow to continue. We shouldn't be starting other trails ie. NASH and "long haulers" until CD12 is complete.
If they are truly meant to attract new talent, then I'm all for it, there is a breakdown in the proxy information, Nader will stand to receive 5.5m shares, or $19.7m.
I just don't get it, clearly the tide has turned on Nader, especially with many of the longs, while they still support and believe in Leronlimab. So if you have Nader's ear or the ability to get it, why not step in and help him out now, he may not be around the end of the year. We have a vote on September 30th, tick tock.
Really?...
He should have pushed back on the FDA, when we completed the combo trial for 350mg. Then they asked for 700mg mono, which he just said on the CC the FDA will make us do a FULL phase 3 trial for mono, so that was a waste of time money and effort. We had something like 81% efficiency with 350mg, the next approved drug was 42% range. We should have been able to move forward with 350mg, then if the FDA wanted a 700mg mono we could start. DELAY DELAY DELAY and $$$$
Again,
Looking back at the proxy. The compensation package is roughly;
Nader 5.5m shares or $19.7m
Scott Kelly 1.75m shares or $6.125m
Mike Mulholland 400k shares or $1.4m
Nitya G. Ray, 850k shares or $2.975 (not sure what he does)
Arian Colachis 320k shares or $1.12m (for a lawyer?)
These funds could be used to get out equity positive, instead of lining their pockets.
Everyone has their chance to voice their opinion and either choose to vote him in or out. It is VERY important for people to vote. I think this last go around caused him to lose quite a bit of long support. No EUA, and that whole compensation lie. A month or so requests 100m shares, states 10-15% will be used on future funding if needed. A month later requests use of 25% for a comp bump, 5.5% of which will go to him, at todays prices is $19m...
Yes,
That is the case, but are you hearing anything else?
I would hope the company is accelerating enrollment, just in case. Per the last call we were at 210, which is just over 50% of what we need, add 28 days... Realistically we're looking at the end of the year if the trial continues.
Still on for the 23rd?
NP's comp package this year is $9.7m
If we got the same buyout $21b. Which would equate to roughly $30/share. Those shares would be worth $165m
Wow, $20m for Nader, just in stock.
What is this based on? Now you're just throwing out things to see if they stick. They haven't even tapped into the 100m that was just authorized.
There are several tiers to NASDAQ, $4/share being the easiest avenue. We have been holding strong at the 2nd tier $3/share, the only thing we're missing on this level as stated several times over several calls is positive equity, $4-5m. Currently I believe we are -$2m. Management has stated they will perform a small offering within 24-48 hours and then will satisfy that requirement. As stated, even if we were at $30/share ultimately it is up to NASDAQ to move forward or not. We meet, or can meet the requirements, it is now up to NASDAQ if they feel the path forward is justified.
Maybe they should announce their intentions publicly? I mentioned this before, for all we know the company has been getting offers, but are turned away, as management feels they should be considerably higher. I would like to know at what point an offer is brought to shareholders? Who determines that? If I made an offer to buy the company at $10/share right now, would that be turned down, would the share holders get to vote?
The only thing I can think of, is the company is setting up for a buyout. We have many phase 2 trials started/approved, HIV completed, Covid CD12 ready for intrim. Nader spent quite a bit of time talking about IMMU's purchase, and stated the buyout would need to be higher, why focus on another company at all during a company call? We had several doctors (unpaid) telling the world what they saw. And this compensation package. If it is to last the next 10 years, why do we need to approve so many shares right now? We now know LL crosses the blood brain barrier, which will be HUGE. This will be bigger than Humaria.
I too hope they decide not to move forward with phase 3 on m/m population. If we get the EUA for S/C I don't see why they can't use our phase 2 m/m to allow usage.
We were down as expected, but held pretty good. I expected a larger drop, I knew if we dipped below $3, it was just a dip and would close above $3. But we recovered quickly and held, never dipping below $3. Mullholland has been going back and forth with Nasdaq for a few weeks now, I hope they have ironed out any concerns and came up with a path forward. next 3-4 weeks should be interesting with possible uplist and CD12 results. Hopefully the company will share some prelim data from what they're seeing as an early indication.
At the end of the day, with all of the positives, and negatives. There are several factors that an investor should be focused on. 1, the FDA (whether you believe it is against us or not), has looked at all of the data Cytodyn has provided over the years, and had continuously advanced trials, and approved new trials, at anytime they could have said no, so they must seem something positive in Leronlimab. Secondly, all of our scientific board advisors, are well respected in their fields of medicine, and have no doubt analyzed the data prior to associating their name with this drug/company. I can not imagine anyone risking their reputation which took a lifetime to build, on something they didn't believe in, and know is real. The science will prevail!
Investment banking and research firm H.C. Wainwright said it would maintain a “neutral” rating after CytoDyn announced its Covid results in August, because it’s not clear the FDA will accept them. The firm gives CytoDyn an 85 percent probability of approval for its HIV indications and 50 percent for Covid.
As long as we continue to close above $2 there is a chance. At $3/share I believe the only thing missing is positive equity, which the company said they can do a small raise in 24-48 hours. That being said, on the CC, Nader said at the end of the day it's up to NASDAQ if they want us to be on or not, whether we're sitting at $3/share or $30/share.
What happened to your 9/23 event? Doesn't that make you still feel positive or is that finished now?
Well between your 23rd comment the other day, and the hint of is the price holds when asked about your confidence if the call would effect the news, I would say uplisting is what you were referring to.
Inquiring minds want to know what is the news? Anyone can say news will be out.